IRIS
POTESTIO, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.117
EU - Europa 990
AS - Asia 589
AF - Africa 60
OC - Oceania 8
SA - Sud America 4
Totale 2.768
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.098
DE - Germania 510
SG - Singapore 447
IT - Italia 236
IN - India 60
CN - Cina 59
CI - Costa d'Avorio 52
FR - Francia 45
FI - Finlandia 43
IE - Irlanda 37
NL - Olanda 29
GB - Regno Unito 26
UA - Ucraina 14
CA - Canada 11
ES - Italia 10
BG - Bulgaria 9
JP - Giappone 9
AU - Australia 8
MX - Messico 7
PT - Portogallo 6
PL - Polonia 5
RO - Romania 5
RS - Serbia 5
BR - Brasile 4
EG - Egitto 4
HK - Hong Kong 4
ID - Indonesia 4
BE - Belgio 3
CZ - Repubblica Ceca 2
DZ - Algeria 2
IL - Israele 2
PK - Pakistan 2
SE - Svezia 2
DK - Danimarca 1
GL - Groenlandia 1
LT - Lituania 1
NG - Nigeria 1
SI - Slovenia 1
TR - Turchia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.768
Salva come PNG Salva come JPEG
Città #
Singapore 365
Chandler 176
Ashburn 127
Krefeld 118
Santa Clara 79
Bad Bellingen 43
Naples 41
Lawrence 30
Amsterdam 29
Lappeenranta 27
Dublin 25
Rome 23
Boston 20
Milan 20
Millbury 18
Kronberg 17
Seattle 17
Helsinki 16
Menlo Park 14
Los Angeles 13
Pune 13
New York 11
Arezzo 10
Fairfield 10
Chennai 9
Sofia 9
Washington 9
Wilmington 9
Des Moines 8
Freiburg im Breisgau 8
Qingdao 8
Boardman 7
Catania 7
Dallas 7
Madrid 7
Mexico City 7
Mumbai 7
Woodbridge 7
Florence 6
Melbourne 6
Rietheim-Weilheim 6
Xi'an 6
Council Bluffs 5
Frankfurt am Main 5
Fremont 5
Giffoni Valle Piana 5
Harbin 5
Houston 5
Lewisham 5
London 5
Munich 5
Shanghai 5
Turin 5
Coimbra 4
Genoa 4
Kochi 4
Monastier di Treviso 4
Nuremberg 4
Perugia 4
Sassari 4
Warsaw 4
Zhengzhou 4
Albano Laziale 3
Bad Durrheim 3
Brussels 3
Bucharest 3
Chicago 3
Edinburgh 3
Hyderabad 3
Karlsruhe 3
Modena 3
Roccasecca 3
Rottweil 3
Tokyo 3
Treviso 3
Waukesha 3
Amiens 2
Atlanta 2
Bhundsi 2
Cairo 2
Castellammare di Stabia 2
Chengdu 2
Clifton 2
Cologne 2
Corteolona 2
Elora 2
Germantown 2
Guangzhou 2
Hazlet 2
Jaipur 2
Jakarta 2
Kagoya 2
Kerken 2
Lecce 2
Marnate 2
Napoli 2
New Delhi 2
North Liberty 2
Paris 2
Pavia 2
Totale 1.576
Salva come PNG Salva come JPEG
Nome #
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 324
A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis 114
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 75
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 63
A practical guide to recognize allergic and immunologic skin diseases: diagnosis at first sight 52
Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab 48
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 44
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 43
Airborne and systemic allergic contact dermatitis due to corticosteroids 35
Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis 35
Tralokinumab in elderly atopic dermatitis 33
Alcohol flushing during dupilumab therapy: an emerging adverse event 31
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 31
Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops 29
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 28
New frontiers in personalized medicine in psoriasis 28
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 28
The effects of dupilumab treatment on general health-related work productivity of adult atopic patients 28
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis 27
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" 27
Kaposi's sarcoma as presentation of HIV in an atopic patient treated with upadacitinib 26
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 26
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 25
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 25
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 25
Scabies outbreak during COVID-19: an Italian experience 25
Acrodermatitis continua of Hallopeau: is apremilast an efficacious treatment option? 25
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab 24
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 24
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 24
Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? 23
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 22
Effects of COVID-19 pandemic on malignant melanoma diagnosis 22
Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation 21
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 21
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 21
A case of acne fulminans successfully treated with photodynamic therapy 21
Teledermatology: a useful tool also after Covid-19 era? 21
COVID-19 vaccination and inflammatory skin diseases 21
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 20
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials 20
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? 20
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 20
Alitretinoin for the treatment of severe chronic eczema of the hands 20
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 19
Zosteriform leiomyomas after Herpes Zoster infection: the isotopic pathway 19
Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?" 19
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 19
Maskne prevalence and risk factors during the COVID-19 pandemic 18
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 18
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study 18
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma 18
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." 18
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 17
Reply to "Psoriasis exacerbation after Covid-19 vaccination: report of 14 cases from a single center" by Sotiriou E et al 17
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? 17
Treating psoriasis in the elderly: biologics and small molecules 17
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 16
Atopic dermatitis exacerbation after Covid‐19 vaccination in Dupilumab‐treated patients 16
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 16
JAK Inhibitors in Psoriatic Disease 15
Reply to "A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine" 15
Herpes Zoster and COVID-19 Vaccination: A Narrative Review 15
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 15
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 15
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 15
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 15
Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience 15
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 15
Granuloma annulare after SARS-CoV-2 vaccination: A case report and a literature review 15
Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic 14
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 14
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 14
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 14
Reply to "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study" 14
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations 14
Letter to the editor regarding article "Hlaca N, Zagar T, Kastelan M, Peternel S, Brajac I, Prpic-Massari L. New-onset lichen planus and lichen planus flare in elderly women after COVID-19 vaccination. J Cosmet Dermatol. 2022;10.1111/jocd.15185" 13
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 13
The Risk of Herpes Virus Infection in Patients With Atopic Dermatitis During Biologic Therapy: A Retrospective Records Based Observational Study 13
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 13
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 13
Cutaneous reactions following booster dose of Covid-19 mRNA vaccination: what we should know 13
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors 13
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire 12
Risk Factors for Psoriasis Flares: A Narrative Review 12
Efficacy of abrocitinib and baricitinib on ‘difficult-to-treat areas’ in patients with atopic dermatitis: a multicentre study 12
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Daungsupawong et al 12
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 12
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 12
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 12
Towards Personalized Medicine in Psoriasis: Current Progress 12
ChatGPT and Dermatology: friends or foes? 11
Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511” 11
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 11
Ulcerated morphea: the importance of the wound care 11
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al 11
Dupilumab for the treatment of adult atopic dermatitis in special populations 11
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 11
Comment on 'Morphoea following COVID-19 vaccination' 11
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study 11
Totale 2.467
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.120
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 3 0 3
2021/2022317 18 5 12 8 17 2 5 31 71 51 33 64
2022/2023616 37 31 20 49 55 70 55 72 72 29 72 54
2023/20241.259 38 92 83 68 52 90 28 114 343 43 179 129
2024/2025774 252 324 86 60 52 0 0 0 0 0 0 0
Totale 2.972